William Blair Weighs in on Exagen’s Q1 Earnings (NASDAQ:XGN)

Exagen Inc. (NASDAQ:XGN) – Research analysts at William Blair boosted their Q1 2025 earnings estimates for Exagen in a research report issued on Wednesday, March 12th. William Blair analyst A. Brackmann now expects that the company will post earnings per share of ($0.20) for the quarter, up from their previous estimate of ($0.24). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.55) EPS.

Several other analysts have also weighed in on XGN. Cantor Fitzgerald reissued an “overweight” rating and set a $8.00 price objective on shares of Exagen in a report on Monday, January 13th. Canaccord Genuity Group upped their price objective on shares of Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd.

Exagen Stock Up 0.6 %

Shares of XGN opened at $3.35 on Friday. Exagen has a 52 week low of $1.30 and a 52 week high of $6.22. The firm has a market capitalization of $59.08 million, a P/E ratio of -3.56 and a beta of 1.40. The company has a 50-day simple moving average of $3.78 and a 200-day simple moving average of $3.57. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of XGN. Verus Capital Partners LLC bought a new position in Exagen in the 3rd quarter valued at $39,000. Stonepine Capital Management LLC boosted its holdings in Exagen by 49.0% in the third quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock valued at $1,651,000 after acquiring an additional 175,701 shares during the last quarter. Palumbo Wealth Management LLC boosted its holdings in Exagen by 13.5% in the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock valued at $355,000 after acquiring an additional 10,340 shares during the last quarter. Corient Private Wealth LLC acquired a new stake in Exagen in the fourth quarter worth about $45,000. Finally, Virtu Financial LLC bought a new stake in Exagen during the 4th quarter worth about $46,000. Institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).